The concurrent administration of galectin-3 and CD47 extensively promoted the remodeling of TAMs and phagocytosis, resulting in an increased T cell response and suppressed tumor growth in an in vivo experimental peritoneal metastasis model [102]. The gene discussed is CD47; the disease is neoplasm.